JANX Earnings Date: Nov 5, 2026 (Estimated) — Janux Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is JANX's next earnings date?
Janux Therapeutics, Inc. (JANX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.47 on revenue of $8.0M.
How did JANX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Janux Therapeutics, Inc. posted EPS of -$0.35 versus the -$0.25 estimate, a miss of 25.0%. Revenue was $10.3M against a $19.1M estimate. The stock's 1-day post-earnings move was -1.6%.
How much does JANX stock move after earnings?
JANX beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.7% (up or down) in the day after earnings.
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.25 | -0.35 | -25.00% | $10.3M | ❌ Miss | -1.55% | -0.62% | +25.71% |
| 2026-05-07 | Q1 2026 | -0.52 | -0.39 | +25.00% | $3.7M | ✅ Beat | -2.51% | -1.03% | -7.08% |
| 2026-02-26 | Q4 2025 | -0.64 | -0.51 | +20.31% | $0 | ✅ Beat | -1.38% | +1.23% | -4.49% |
| 2025-11-06 | Q3 2025 | -0.61 | -0.39 | +36.07% | $10.0M | ✅ Beat | -7.61% | -4.19% | -42.15% |
| 2025-02-27 | Q4 2024 | -0.45 | -0.36 | +20.00% | $0 | ✅ Beat | +2.75% | -3.94% | -9.09% |
| 2024-08-07 | Q2 2024 | -0.31 | -0.11 | +64.52% | $8.9M | ✅ Beat | +3.40% | +13.83% | +16.92% |
| 2024-05-07 | Q1 2024 | -0.33 | -0.30 | +9.09% | $1.3M | ✅ Beat | -9.97% | -22.10% | -30.75% |
| 2024-03-08 | Q4 2023 | -0.40 | -0.25 | +37.50% | $2.5M | ✅ Beat | +0.40% | -0.90% | +0.55% |
Showing last 8 quarters.